Saddled with uncertain outcomes, most firms focused on gene and RNA therapies have had a poor performance record over the past year
Identify turn-around stories early on by tracking their performance over very short periods (from 2 weeks on, by selecting your preferred time frame on the drop-down menu, top right)
An investment focus on high-value drug development collaborations between giant healthcare companies and clinical trial and research firms is a high-stake bet and, potentially, a high-reward strategy
Various degrees of collaboration and license agreements have committed each and every global healthcare firm to large pay-outs tied to sales thresholds, to be achieved by the successful research firm…
…if and when regulatory approval is ultimately granted
The large healthcare firms – often strong contenders in rare disease R&D in their own right – such as AbbVie
The selection does not cover all collaborations currently under way and should be understood as a sampling of an on-going trend worth of careful evaluation
The companion theme "Cell Therapies - Gene Editing" lists additional significant healthcare firms focused on research in advanced genetics